Correlation between toll-like receptor 4 and nucleotide-binding oligomerization domain 2 (NOD2) and pathological severity in dogs with chronic gastrointestinal diseases

Aono, Kimiya; Azuma, Yasutaka; Nabetani, Tomoyo; Hatoya, Shingo; Furuya, Masaru; Miki, Masao; Hirota, Kana; Fujimoto, Yasuyuki; Nishiyama, Kazuhiro; Ogata, Yasuhiro; Mochizuki, Tomofumi; Tani, Hiroyuki

doi:10.1016/j.vetimm.2019.03.003

Cited by 2 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 mRNA expression of TLR4 and NOD2 is dysregulated in CE. 24,25 Supplementation with glycine also decreases the clinical severity and inflammatory infiltrates in animal models of inflammatory enteropathies. 22 A possible explanation for the discordance between our findings and those of previous studies might lie in the smaller number of dogs used in one of these previous cohorts, or the differences in study samples analyzed, as previous studies included only dogs with immunosuppressive -responsive enteropathy 26 and protein-losing enteropathy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum metabolomic profiles in dogs with chronic enteropathy

Walker

Boag

Ottka

et al. 2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Metabolic profiles differ between healthy humans and those with inflammatory bowel disease. Few studies have examined metabolic profiles in dogs with chronic enteropathy (CE). Hypothesis Serum metabolic profiles of dogs with CE are significantly different from those of healthy dogs. Animals Fifty‐five dogs with CE and 204 healthy controls. Methods A cross‐sectional study. The serum concentrations of 99 metabolites measured using a canine‐specific proton nuclear magnetic resonance spectroscopy platform were studied. A 2‐sample unpaired t‐test was used to compare the 2 study samples. The threshold for significance was set at P < .05 with a Bonferroni correction for each metabolite group. Results Nineteen metabolites and 18 indices of lipoprotein composition were significantly different between the CE and healthy dogs. Four metabolites were significantly higher in dogs with CE, including phenylalanine (mean and SD) (healthy: 0.0417 mmol/L; [SD] 0.0100; CE: 0.0480 mmol/L; SD: 0.0125; P value: <.001) and lactate (healthy: 1.8751 mmol/L; SD: 0.7808; CE: 2.4827 mmol/L; SD CE: 1.4166; P value: .003). Fifteen metabolites were significantly lower in dogs with CE, including total fatty acids, and glycine (healthy: 0.2273 mmol/L; SD: 0.0794; CE: 0.1828 mmol/L; SD CE: 0.0517; P value: <.001). Conclusions and Clinical Importance The metabolic profile of dogs with CE is significantly different from that of healthy dogs, this opens novel research avenues to develop better diagnostic and prognostic approaches as well as therapeutic trials.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It suppresses TLR4 and NOD2 signaling in piglets challenged with lipopolysaccharide 23 . mRNA expression of TLR4 and NOD2 is dysregulated in CE 24,25 . Supplementation with glycine also decreases the clinical severity and inflammatory infiltrates in animal models of inflammatory enteropathies 22 .…”

Section: Discussionmentioning

confidence: 99%

Serum metabolomic profiles in dogs with chronic enteropathy

Walker

Boag

Ottka

et al. 2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

What are the potential biomarkers that should be considered in diagnosing and managing canine chronic inflammatory enteropathies?

Sacoor¹,

Barros²,

Montezinho³

2021

Open Vet J.

View full text Add to dashboard Cite

Chronic inflammatory enteropathies in dogs are characterized by persistent or recurrent gastrointestinal signs that lastfor more than 3 weeks. Despite unclear etiopathogenesis, it is considered that a genetic predisposition associated withenvironmental factors, such as dietary antigens and intestinal microbiota, might induce an abnormal immune responsein the host. The diagnosis of this condition requires full investigation in order to exclude all other possible causes. Currently, the observation of clinical signs associated with histopathologic evaluation and systematic therapeutic trials is the gold standard for the diagnosis of chronic enteropathies. Furthermore, diagnosis, monitoring the disease progression, and treatment response evaluation can be exhausting, since this whole process is time-consuming, costly, and partially invasive. Therefore, biomarkers appear as non-invasive tools, which can be useful in evaluating gastrointestinal function, identifying the presence of the disease and assessing its natural progression, monitoring gastrointestinal inflammation, predicting response to treatment, and clinical outcomes. Over the past decade, several studies were conducted in order to explore the clinical utility of biomarkers. Thus, the aim of this dissertation is to provide an overview of the biomarkers considered relevant in the diagnosis and management of dogs with chronic inflammatory enteropathies. The biomarkers addressed in this study may be serological, present in urine and feces, or even tissue-derived. This study argues that biomarkers, in particular calprotectin and calgranulin C, have great potential to be used in clinical practice in the diagnosis and management of affected dogs. However, a single biomarker cannot assuredly predict disease severity, progression, response to treatment, and clinical outcomes. Therefore, in order to achieve greater accuracy, it would be beneficial if these tools are used in conjunction with contemporary ones. Future research is needed with the aim to better determine the usefulness of these tools in chronic inflammatory enteropathies in dogs.

show abstract

Correlation between toll-like receptor 4 and nucleotide-binding oligomerization domain 2 (NOD2) and pathological severity in dogs with chronic gastrointestinal diseases

Cited by 2 publications

References 43 publications

Serum metabolomic profiles in dogs with chronic enteropathy

Serum metabolomic profiles in dogs with chronic enteropathy

What are the potential biomarkers that should be considered in diagnosing and managing canine chronic inflammatory enteropathies?

Contact Info

Product

Resources

About